Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Protective Effect of the Asystasia chelonoides Extracts on Hypertensive Nephropathy Rats

Author(s): Tingting Duan, Minyi Li, Beifeng Lie, Ziyang Lin, Mengqiu Li, Tao Xia, Guixuan Lin, Lanqing Meng, Xiuqing Lu, Zhenghai Li* and Junzheng Yang*

Volume 24, Issue 13, 2023

Published on: 28 March, 2023

Page: [1708 - 1714] Pages: 7

DOI: 10.2174/1389201024666230320120925

Price: $65

conference banner
Abstract

Background: Hypertensive nephropathy (HN) is one kind of kidney disorders caused by long-term uncontrolled hypertension, usually resulting in severe kidney damage, including inflammation and oxidative stress, no matter in cells or tissues, from patients with nephropathy. In recent years, nephropathy accompanied by hypertension is becoming one of the main causes for kidney replacement therapy, but few effective treatments have been reported for HN treatment. Asystasia chelonoides (AC) is a kind of plant with the effects of anti-inflammation, lowering blood pressure, and anti-oxidative stress. Still, the therapeutic effect of AC in HN rats is not clear.

Methods: To establish HN model by feeding high sugar and high fat diet spontaneously hypertensive rats. Blood measurement, HE staining, PAS staining and biochemical analysis and were used to assess the therapeutic effects of AC extracts and western blotting analyzed the underlying mechanisms of AC extracts treatment in the HN rat model.

Results: AC extracts could significantly lower systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean blood pressure (MBP) in HN rats; and reduce the expression of total protein (TP), blood urea nitrogen (BUN), microalbuminuria (MALB), creatinine (Cr), total cholesterol (TC), triglyceride (TG), and low-density lipoprotein-cholesterol (LDL-C) concentrations, and also could down-regulate expression of IL-6, MDA and AGEs, up-regulate the expression of SOD in HN rats; HE staining and PAS staining demonstrated that AC extracts could alleviate the histopathological changes in HN rats; western blotting demonstrated that AC extracts could up-regulate the expression of PPARγ and down-regulate the expression of TGFβ1 and NF-кB in HN rats.

Conclusion: The finding of the article demonstrated that AC extracts had the better therapeutic effect for HN, and provided the pharmacological evidences for AC extracts treatment for HN.

« Previous
Graphical Abstract

[1]
Rivas, A.M.; Pena, C.; Kopel, J.; Dennis, J.A.; Nugent, K. Hypertension and hyperthyroidism: Association and pathogenesis. Am. J. Med. Sci., 2021, 361(1), 3-7.
[http://dx.doi.org/10.1016/j.amjms.2020.08.012] [PMID: 33012487]
[2]
Kearney, P.M.; Whelton, M.; Reynolds, K.; Muntner, P.; Whelton, P.K.; He, J. Global burden of hypertension: Analysis of worldwide data. Lancet, 2005, 365(9455), 217-223.
[http://dx.doi.org/10.1016/S0140-6736(05)17741-1] [PMID: 15652604]
[3]
Collins, A.J.; Foley, R.N.; Chavers, B.; Gilbertson, D.; Herzog, C.; Johansen, K.; Kasiske, B.; Kutner, N.; Liu, J.; St, P.W.; Guo, H.; Gustafson, S.; Heubner, B.; Lamb, K.; Li, S.; Li, S.; Peng, Y.; Qiu, Y.; Roberts, T.; Skeans, M.; Snyder, J.; Solid, C.; Thompson, B.; Wang, C.; Weinhandl, E.; Zaun, D.; Arko, C.; Chen, S.C.; Daniels, F.; Ebben, J.; Frazier, E.; Hanzlik, C.; Johnson, R.; Sheets, D.; Wang, X.; Forrest, B.; Constantini, E.; Everson, S.; Eggers, P.; Agodoa, L. United States renal data system 2011 annual data report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis, 2012, 59(A7), e1-e420.
[http://dx.doi.org/10.1053/j.ajkd.2011.11.015]
[4]
Christiansen, R.E.F.; Roald, A.B.; Tenstad, O.; Iversen, B.M. Renal hemodynamics during development of hypertension in young spontaneously hypertensive rats. Kidney Blood Press. Res., 2002, 25(5), 322-328.
[http://dx.doi.org/10.1159/000066792] [PMID: 12435879]
[5]
Li, Y.; Sun, X.; Yu, Y. Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. Biomed Res. Int., 2013, 2013, 795103.
[http://dx.doi.org/10.1155/2013/795103]
[6]
Troudi, A.; Amara, I.B.; Soudani, N.; Samet, A.M.; Zeghal, N. Oxidative stress induced by gibberellic acid on kidney tissue of female rats and their progeny: Biochemical and histopathological studies. J. Physiol. Biochem., 2011, 67(3), 307-316.
[http://dx.doi.org/10.1007/s13105-011-0076-4] [PMID: 21305369]
[7]
Ojiako, O.A.; Chikezie, P.C.; Ogbuji, A.C. Blood glucose level and lipid profile of alloxan-induced hyperglycemic rats treated with single and combinatorial herbal formulations. J. Tradit. Complement. Med., 2016, 6(2), 184-192.
[http://dx.doi.org/10.1016/j.jtcme.2014.12.005] [PMID: 27114943]
[8]
Mugabo, P.; Raji, I.A. Effects of aqueous leaf extract of Asystasia gangetica on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats. BMC Complement. Altern. Med., 2013, 13(1), 283.
[http://dx.doi.org/10.1186/1472-6882-13-283] [PMID: 24160568]
[9]
Mohamed Saleem, T.S.; Sujatha, D.; Saleem, TsM.; Chetty, C.M.; Ranganayakulu, D. Potential antidiabetic and antioxidant activities of Morus indica and Asystasia gangetica in alloxan-induced diabetes mellitus. J. Exp. Pharmacol., 2010, 2, 29-36.
[http://dx.doi.org/10.2147/JEP.S8947] [PMID: 27186088]
[10]
Ojiako, O.A.; Chikezie, P.C.; Ogbuji, A.C. Radical scavenging potentials of single and combinatorial herbal formulations in vitro. J. Tradit. Complement. Med., 2016, 6(2), 153-159.
[http://dx.doi.org/10.1016/j.jtcme.2014.11.037] [PMID: 27114938]
[11]
Sarnak, M.J.; Levey, A.S.; Schoolwerth, A.C.; Coresh, J.; Culleton, B.; Hamm, L.L.; McCullough, P.A.; Kasiske, B.L.; Kelepouris, E.; Klag, M.J.; Parfrey, P.; Pfeffer, M.; Raij, L.; Spinosa, D.J.; Wilson, P.W. Kidney disease as a risk factor for development of cardiovascular disease. Hypertension, 2003, 42(5), 1050-1065.
[http://dx.doi.org/10.1161/01.HYP.0000102971.85504.7c] [PMID: 14604997]
[12]
Freedman, B.I.; Cohen, A.H. Hypertension-attributed nephropathy: What’s in a name? Nat. Rev. Nephrol., 2016, 12(1), 27-36.
[http://dx.doi.org/10.1038/nrneph.2015.172] [PMID: 26553514]
[13]
Williams, B.; Mancia, G. Ten commandments of the 2018 ESC/ESH HTN guidelines on hypertension in adults. Eur. Heart J., 2018, 39(33), 3007-3008.
[http://dx.doi.org/10.1093/eurheartj/ehy439] [PMID: 30990869]
[14]
Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr; Collins, K.J.; Dennison Himmelfarb, C.; DePalma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; MacLaughlin, E.J.; Muntner, P.; Ovbiagele, B.; Smith, S.C., Jr; Spencer, C.C.; Stafford, R.S.; Taler, S.J.; Thomas, R.J.; Williams, K.A., Sr; Williamson, J.D.; Wright, J.T., Jr 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of Cardiology/American heart association task force on clinical practice guidelines. Hypertension, 2018, 71(6), e13-e115.
[http://dx.doi.org/10.1161/HYP.0000000000000065] [PMID: 29133356]
[15]
Cheung, A.K.; Chang, T.I.; Cushman, W.C.; Furth, S.L.; Hou, F.F.; Ix, J.H.; Knoll, G.A.; Muntner, P.; Pecoits-Filho, R.; Sarnak, M.J.; Tobe, S.W.; Tomson, C.R.V.; Mann, J.F.E. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int., 2021, 99(3), S1-S87.
[http://dx.doi.org/10.1016/j.kint.2020.11.003] [PMID: 33637192]
[16]
Abdel-Zaher, A.O.; Farghaly, H.S.M.; El-Refaiy, A.E.M.; Abd-Eldayem, A.M. Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms. Biomed. Pharmacother., 2017, 95, 944-955.
[http://dx.doi.org/10.1016/j.biopha.2017.08.078] [PMID: 28915536]
[17]
Abdel-Zaher, A.O.; Farghaly, H.S.M.; El-Refaiy, A.E.M.; Abd-Eldayem, A.M. Protective effect of the standardized leaf extract of Ginkgo biloba (EGb761) against hypertension-induced renal injury in rats. Clin. Exp. Hypertens., 2018, 40(8), 703-714.
[http://dx.doi.org/10.1080/10641963.2018.1425421] [PMID: 29351002]
[18]
Chen, Z.; Peng, Y.; Yang, F.; Qiang, X.; Chen, Y.; Chen, Y.; Cao, L.; Liu, C.; Zhang, J. Traditional chinese medicine injections combined with antihypertensive drugs for hypertensive nephropathy: A network Meta-Analysis. Front. Pharmacol., 2021, 12, 740821.
[http://dx.doi.org/10.3389/fphar.2021.740821] [PMID: 34744724]
[19]
Zhu, J.; Zhang, Y.; Yang, C. Protective effect of 3-n-butylphthalide against hypertensive nephropathy in spontaneously hypertensive rats. Mol. Med. Rep., 2015, 11(2), 1448-1454.
[http://dx.doi.org/10.3892/mmr.2014.2791] [PMID: 25352064]
[20]
Chen, L.; Wu, J.; Xu, H.; Chen, J.; Xie, X. Effects of tanshinone combined with valsartan on hypertensive nephropathy and its influence on renal function and vascular endothelial function. Am. J. Transl. Res., 2021, 13(5), 4788-4795.
[PMID: 34150059]
[21]
Du, H.; Xiao, G.; Xue, Z.; Li, Z.; He, S.; Du, X.; Zhou, Z.; Cao, L.; Wang, Y.; Yang, J.; Wang, X.; Zhu, Y. QiShenYiQi ameliorates salt-induced hypertensive nephropathy by balancing ADRA1D and SIK1 expression in Dahl salt-sensitive rats. Biomed. Pharmacother., 2021, 141, 111941.
[http://dx.doi.org/10.1016/j.biopha.2021.111941] [PMID: 34328102]
[22]
Achari, R.; Laddu, A. Terazosin: A new alpha adrenoceptor blocking drug. J. Clin. Pharmacol., 1992, 32(6), 520-523.
[http://dx.doi.org/10.1177/009127009203200605] [PMID: 1353083]
[23]
Papadopoulos, D.P.; Papademetriou, V. Metoprolol succinate combination in the treatment of hypertension. Angiology, 2009, 60(5), 608-613.
[http://dx.doi.org/10.1177/0003319708326450] [PMID: 19033265]
[24]
Elliott, W.J.; Bistrika, E.A. Perindopril arginine and amlodipine besylate for hypertension: A safety evaluation. Expert Opin. Drug Saf., 2018, 17(2), 207-216.
[http://dx.doi.org/10.1080/14740338.2018.1397129] [PMID: 29065722]
[25]
Ram, C.V.S.; Ram, S. Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. Expert Rev. Cardiovasc. Ther., 2011, 9(1), 9-19.
[http://dx.doi.org/10.1586/erc.10.163] [PMID: 21166525]
[26]
Staessen, J.; Fagard, R.; Lijnen, P.; Amery, A. Captopril in the treatment of hypertension. Acta Clin. Belg., 1982, 37(3), 164-184.
[http://dx.doi.org/10.1080/22953337.1982.11718860] [PMID: 6214916]
[27]
Zhang, H.; Park, Y.; Wu, J.; Chen, X.; Lee, S.; Yang, J.; Dellsperger, K.C.; Zhang, C. Role of TNF-α in vascular dysfunction. Clin. Sci., 2009, 116(3), 219-230.
[http://dx.doi.org/10.1042/CS20080196] [PMID: 19118493]
[28]
Chen, L.; Frister, A.; Wang, S.; Ludwig, A.; Behr, H.; Pippig, S.; Li, B.; Simm, A.; Hofmann, B.; Pilowski, C.; Koch, S.; Buerke, M.; Rose-John, S.; Werdan, K.; Loppnow, H. Interaction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances IL-6 and MCP-1 production. Am. J. Physiol. Heart Circ. Physiol., 2009, 296(4), H987-H996.
[http://dx.doi.org/10.1152/ajpheart.01158.2008] [PMID: 19168721]
[29]
Yoshimatsu, Y.; Wakabayashi, I.; Kimuro, S.; Takahashi, N.; Takahashi, K.; Kobayashi, M.; Maishi, N.; Podyma-Inoue, K.A.; Hida, K.; Miyazono, K.; Watabe, T. TNF‐α enhances TGF‐β‐induced endothelial‐to‐mesenchymal transition via TGF‐β signal augmentation. Cancer Sci., 2020, 111(7), 2385-2399.
[http://dx.doi.org/10.1111/cas.14455] [PMID: 32385953]
[30]
Naseem, R.; Adam, A.M.; Khan, F.; Dossal, A.; Khan, I.; Khan, A.; Paul, H.; Jawed, H.; Aslam, A.; Syed, F.M.; Niazi, M.A.; Nadeem, S.; Khan, A.; Zia, A.; Arshad, M.H. Prevalence and characteristics of resistant hypertensive patients in an Asian population. Indian Heart J., 2017, 69(4), 442-446.
[http://dx.doi.org/10.1016/j.ihj.2017.01.012] [PMID: 28822508]
[31]
Rao, M.S.; Papreddy, K.; Musunuri, S.; Okonkwo, A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. In Vivo, 2002, 16(2), 145-152.
[PMID: 12073774]
[32]
Rao, M.S.; Reddy, J.K. PPAR? in the pathogenesis of fatty liver disease. Hepatology, 2004, 40(4), 783-786.
[http://dx.doi.org/10.1002/hep.20453] [PMID: 15382158]
[33]
Minyi Li, Beifeng Lie, Tingting Duan, Deqi Chen, Tao Xia, Heng Xie, Guixuan Lin, Junzheng Yang, and Zhenghai Li. The protective effect of Bajijiasu on the treatment of hypertensive nephropathy in rats. Curr. Mol. Pharmacol., 2022, 1(3), 255-269.
[http://dx.doi.org/10.2174/1874467215666221005141210]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy